Role of Inflammation and the Immune System in the Progression of Osteoarthritis

Woodell-May, Jennifer; Sommerfeld, Sven D.

doi:10.1002/jor.24457

Cited by 265 publications

(195 citation statements)

References 35 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…The innate and adaptive immune systems protect the host from infection, with essential roles for leukocytes overlapping between both systems, as displayed in Figure 4 . Specifically, monocytes, macrophages, neutrophils, and natural killer cells have pivotal roles in the innate system, whereas lymphocytes and their subsets play similar roles in the adaptive immune system [ 107 ].…”

Section: Innate and Adaptive Immunomodulatory Capacities Of Prpmentioning

confidence: 99%

“…The adaptive system includes B lymphocytes (B cells), which bind antigens, and regular T lymphocytes (Treg), which coordinate the elimination of the pathogens. T cells can be broadly categorized into helper T cells (Th cells) and cytotoxic T cells (Tc cells, also known as T killer cells) [ 107 ]. The Th cells are further divided into Th1, Th2, and Th17 cells, with critical functions in inflammation.…”

Section: Innate and Adaptive Immunomodulatory Capacities Of Prpmentioning

confidence: 99%

See 1 more Smart Citation

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Everts

Onishi²,

Jayaram

et al. 2020

IJMS

505

418

View full text Add to dashboard Cite

Emerging autologous cellular therapies that utilize platelet-rich plasma (PRP) applications have the potential to play adjunctive roles in a variety of regenerative medicine treatment plans. There is a global unmet need for tissue repair strategies to treat musculoskeletal (MSK) and spinal disorders, osteoarthritis (OA), and patients with chronic complex and recalcitrant wounds. PRP therapy is based on the fact that platelet growth factors (PGFs) support the three phases of wound healing and repair cascade (inflammation, proliferation, remodeling). Many different PRP formulations have been evaluated, originating from human, in vitro, and animal studies. However, recommendations from in vitro and animal research often lead to different clinical outcomes because it is difficult to translate non-clinical study outcomes and methodology recommendations to human clinical treatment protocols. In recent years, progress has been made in understanding PRP technology and the concepts for bioformulation, and new research directives and new indications have been suggested. In this review, we will discuss recent developments regarding PRP preparation and composition regarding platelet dosing, leukocyte activities concerning innate and adaptive immunomodulation, serotonin (5-HT) effects, and pain killing. Furthermore, we discuss PRP mechanisms related to inflammation and angiogenesis in tissue repair and regenerative processes. Lastly, we will review the effect of certain drugs on PRP activity, and the combination of PRP and rehabilitation protocols.

show abstract

Section: Innate and Adaptive Immunomodulatory Capacities Of Prpmentioning

confidence: 99%

Section: Innate and Adaptive Immunomodulatory Capacities Of Prpmentioning

confidence: 99%

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Everts

Onishi²,

Jayaram

et al. 2020

IJMS

505

418

View full text Add to dashboard Cite

show abstract

“…The innate and adaptive immune systems protect the host from infection, with essential roles for leukocytes overlapping between both systems, as displayed in figure 4. Specifically, monocytes, macrophages, neutrophils, and natural killer cells have pivotal roles in the innate system, whereas lymphocytes and their subsets play similar roles in the adaptive immune system (104).…”

Section: Platelets and Leukocytes Play Pivotal Roles In Innate And Admentioning

confidence: 99%

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Everts¹,

Onishi²,

Jayaram³

et al. 2020

Preprint

157

120

View full text Add to dashboard Cite

Emerging autologous cellular therapies that utilize platelet-rich plasma (PRP) applications have the potential to play adjunctive roles in a variety of regenerative medicine treatment plans. There is a global unmet need for tissue repair strategies to treat musculoskeletal (MSK) and spinal disorders, osteoarthritis (OA), and patients with chronic complex and recalcitrant wounds. PRP therapy is based on the fact that platelet growth factors (PGFs) support the three phases of wound healing and repair cascade (inflammation, proliferation, remodeling). Many different PRP formulations have been evaluated, originating from human, in vitro, and animal studies. However, recommendations from in vitro and animal research often lead to different clinical outcomes because it is difficult to translate non-clinical study outcomes and methodology recommendations to human clinical treatment protocols. In recent years, progress has been made in understanding PRP technology and the concepts for bioformulation, and new research directives and new indications have been suggested. In this review, we will discuss recent developments regarding PRP preparation and composition regarding platelet dosing, leukocyte activities concerning innate and adaptive immunomodulation, serotonin (5-HT) effects and pain killing. Furthermore, we discuss PRP mechanisms related to inflammation and angiogenesis in tissue repair and regenerative processes. Lastly, we will review the effect of certain drugs on PRP activity, and the combination of PRP and rehabilitation protocols.

show abstract

“…Enrico Ragni 1 , Laura Mangiavini 2,3 , Marco Viganò 1 , Anna Teresa Brini 4,5 , Giuseppe Michele Peretti 2,3 , Giuseppe Banfi 2,6 and Laura de Girolamo 1, *…”

Section: Management Of Osteoarthritis During the Covid-19 Pandemicunclassified

“…Inflammation, biomechanical alterations, and the immune response play an important role. 2 Indeed, risk factors are sex, obesity, genetic factors, and mechanical factors. 3 In the development of OA, the whole joint undergoes a complex remodeling, which in turn ends in degeneration.…”

Section: Aim Of the Reviewmentioning

confidence: 99%

Management of Osteoarthritis During the COVID‐19 Pandemic

Ragni

Mangiavini

Viganò

et al. 2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The pandemic spread of the new coronavirus disease 2019 (COVID‐19) infection in China first, and all over the world at present, has become a global health emergency due to the rapidly increasing number of affected patients. Currently, a clear relationship between COVID‐19 infection incidence and/or complications due to chronic or occasional treatments for other pathologies is still not clear, albeit the COVID‐19 pandemic may condition the treatment strategy of complex disorders, such as osteoarthritis (OA). Importantly, OA is the most common age‐related joint disease, affecting more than 80% of people older than the age of 55, an age burden also shared with the highest severity in COVID‐19 patients. OA patients often show a large array of concomitant pathologies, such as diabetes, inflammation, and cardiovascular diseases that are again shared with COVID‐19 patients and may therefore increase complications. Moreover, different OA treatments, such as NSAIDs, paracetamol, corticosteroids, opioids, or other molecules have a wide array of iatrogenic effects, potentially increasing COVID‐19 secondary infection incidence or complications. In this review we critically analyze the evidence on either negative or positive effects of drugs commonly used to manage OA in this particular scenario. This would provide orthopedic surgeons in particular, and physicians, pharmacologists, and clinicians in general, a comprehensive description about the safety of the current pharmacological approaches and a decision‐making tool to treat their OA patients as the coronavirus pandemic continues.

show abstract

Role of Inflammation and the Immune System in the Progression of Osteoarthritis

Cited by 265 publications

References 35 publications

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Management of Osteoarthritis During the COVID‐19 Pandemic

Contact Info

Product

Resources

About